These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37452459)

  • 1. Neoadjuvant chemoradiotherapy followed by oesophagectomy may be the optimal treatment option for lower thoracic oesophageal cancer with supraclavicular lymph node metastasis: An inverse probability of treatment-weighted analysis of SEER database.
    Chang X; Liu J; Zhao Y; Shi A; Yu H; Yu R; Wang W
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):676-683. PubMed ID: 37452459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis.
    Xu HY; Wu SX; Luo HS; Chen CY; Lin LX; Huang HC
    Radiat Oncol; 2018 Oct; 13(1):200. PubMed ID: 30326912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.
    Honma Y; Hokamura N; Nagashima K; Sudo K; Shoji H; Iwasa S; Takashima A; Kato K; Hamaguchi T; Boku N; Umezawa R; Ito Y; Itami J; Koyanagi K; Igaki H; Tachimori Y
    Anticancer Res; 2017 Jul; 37(7):3741-3749. PubMed ID: 28668869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Miyata H; Yamasaki M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg; 2015 Aug; 262(2):280-5. PubMed ID: 25211269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
    Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
    J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field.
    Schurink B; Seesing MFJ; Goense L; Mook S; Brosens LAA; Mohammad NH; Ruurda JP; Roeling TAP; Bleys RLAW; van Hillegersberg R
    Eur J Surg Oncol; 2019 Mar; 45(3):454-459. PubMed ID: 30503227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
    BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiation for oesophageal cancer: the choice of treatment modality.
    Kitti PM; Faltinova M; Kauppi J; Räsänen J; Saarto T; Seppälä T; Anttonen AM
    Radiat Oncol; 2023 May; 18(1):93. PubMed ID: 37259100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study.
    Park JK; Kim JJ; Moon SW; Cho DG
    J Cardiothorac Surg; 2018 Jun; 13(1):62. PubMed ID: 29880029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Huang CH; Shih LH; Chen SW; Li SH
    PLoS One; 2018; 13(6):e0198800. PubMed ID: 29889869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical lymph node dissection for clinically submucosal carcinoma of the thoracic esophagus.
    Kosugi S; Kawaguchi Y; Kanda T; Ishikawa T; Sakamoto K; Akaike H; Fujii H; Wakai T
    Ann Surg Oncol; 2013 Nov; 20(12):4016-21. PubMed ID: 23892526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 19. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does cervical lymph node recurrence after oesophagectomy or definitive chemoradiotherapy for thoracic oesophageal squamous cell carcinoma benefit from salvage treatment?
    Yuan X; Lv J; Dong H; Wang J
    Interact Cardiovasc Thorac Surg; 2017 May; 24(5):792-795. PubMed ID: 28453803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.